Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2002

View Archived Issues

Boehringer Ingelheim and Genetronics sign gene therapy research agreement

Serono and Pfizer to copromote Rebif in the U.S.

Phase III patient enrollment complete for histrelin implant

Cell-based gene therapy research collaboration announced

Dyax acquires exclusive rights to a newly discovered prostate cancer target

Another major launch for Alcon's prostaglandin analogue for glaucoma

Russian researchers investigate profile of himantane, a potential new agent for Parkinson's disease

MetaPhore's lead SOD mimetics effective in animal models of pain and asthma

Antiplatelet/antithrombotic efficacy demonstrated for P2Y12 receptor antagonists

Ligands for EAATs identified in series of 5-methylglutamate analogues

Positive effects on aggressive behavior and learning reported for NVP-SRA-880

Desired profile confirmed for humanized PRO-140

Novel factor Xa inhibitor and oral prodrug presented at IUPHAR 2002 by Kissei

Novel FTase inhibitors in early development at Janssen

Vertex presents new caspase inhibitors for use in cancer, etc.

New p38alpha kinase inhibitors emerge from Scios R&D

Pfizer presents prostaglandin EP4 agonists for bone disorders

Synthesis, biological evaluation and use of NK1 antagonists reported by Roche

Estrogen receptor modulators with wide therapeutic application designed by Merck team

UCB claims novel GABA-A antagonists with antiepileptic activity

Clinical data support once-daily emtricitabine for HIV infection

Chiron licenses hepatitis C targets to Abbott

MedImmune receives FluMist complete response letter

Amrad discontinues development of AM-365

Enzon to reacquire Oncaspar rights from Aventis

Actimid shows antitumor activity in multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.